Clinical trials: Hepatitis C, completed
Hepatitis C, Chronic Hepatitis C
Drug Interaction Study to Assess the Effect of Co-Administered Miravirsen and Telaprevir in Healthy Subjects
The purpose of this study is to assess the safety, tolerability, and affect on blood levels of miravirsen and telaprevir when administered together.
- Trial name
- NCT01646489
- Testing
- Miravirsen sodium, Telaprevir
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Santaris Pharma A/S
Hepatitis C
Increasing HCV Linkage to Care Among People Who Inject Drugs
Our study will test the effectiveness of a simplified approach to delivering Hepatitis C Virus (HCV) care in a street-based mobile medical clinic among people who inject drugs in increasing treatment initiation, retention, and…
- Trial name
- NCT04741750
- Testing
- Simplified HCV care within a mobile medical unit
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Family Health Centers of San Diego
Hepatitis C
T Regulatory Cells in Hepatitis c Infected Patients
Chronic hepatitis C infection is a global worldwide health problem with an increasing burden year-by-year, particularly in areas with a high endemicity like Egypt .
- Trial name
- NCT03186235
- Testing
- Flow cytometry
- Where
- Egypt
- Volunteers
- 88 people
- Sponsor
- Assiut University
Hepatitis C, Depression
Paroxetine for the Treatment of Interferon Related Side Effects for Hepatitis C
A.OVERVIEW This is a 26 week study examining the ability of paroxetine (Paxil) to prevent the development of depression and neurotoxicity in patients receiving either 3 million units of subcutaneous IFN(interferon-alpha-2b) 3…
- Conditions
- Hepatitis C, Depression, Interferon-alpha Associated Side Effects
- Trial name
- NCT00209118
- Testing
- paroxetine
- Volunteers
- 60 people
- Sponsor
- Emory University
Chronic Hepatitis C Infection
Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection
This is a phase 3, double-blinded, multicenter study. The study will consist of 2 substudies: Substudy 1 (SS1) will be double-blinded and enroll non-cirrhotic subjects and Substudy 2 (SS2) will be open label and enroll subjects…
- Trial name
- GIFT I (NCT02023099)
- Testing
- ABT-450/r/ABT-267
- Volunteers
- 363 people
- Sponsor
- AbbVie
Hepatitis C
Phase III Randomized Study of High Vs Standard Dose of Interferon Alfa for Chronic Hepatitis C
OBJECTIVES: I. Determine whether the initial response to interferon alfa (IFN-A) can be increased by starting at a dose of 5 MU three times a week in patients with chronic hepatitis C. II.
- Trial name
- NCT00004804
- Testing
- interferon alfa
- Volunteers
- 57 people
- Sponsor
- National Center for Research Resources (NCRR)
Chronic Hepatitis C Virus Infection
Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients
enrolled participants were treated orally with SOF plus a fixed dose combination of OBV/PTV/r plus RBV.
- Trial name
- NCT04391985
- Testing
- SOF plus (OBV/PTV/r) plus RBV
- Where
- Egypt
- Volunteers
- 113 people
- Sponsor
- Beni-Suef University
Hepatitis C
Prophylaxis of Psychiatric Symptoms During Anti-HCV Treatment
The treatment of chronic hepatitis C with peginterferon and ribavirin is highly effective but is hampered by peginterferon-induced psychopathology.
- Trial name
- NCT00133276
- Testing
- Escitalopram
- Where
- 3 sites in Netherlands
- Volunteers
- 80 people
- Sponsor
- Foundation for Liver Research
Chronic Hepatitis C, End Stage Renal Disease
Interferon Treatment for Patients With Chronic Hepatitis C and End Stage Renal Disease
The treatment response with conventional interferon alpha alone in patients with end stage renal disease and chronic hepatitis C is about 33-39%. However, the drop-out rate is 17-29.6%.
- Trial name
- NCT00172809
- Testing
- Peginterferon alfa-2a, Interferon alfa-2a
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- National Taiwan University Hospital
HIV Infections, Hepatitis B
Pilot Study of HIV and Hepatitis B and C Screening in Surgery
The purpose of the OPDEP pilot study is to assess the feasibility of implementing a pre-operative HIV / HCV / HBV screening proposal for all persons over 18 years of age and refer for surgical intervention under general…
- Conditions
- HIV Infections, Hepatitis B, Hepatitis C
- Trial name
- OPDEP (NCT03088995)
- Testing
- Pilot study
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
Hepatitis C Virus
TMC435-TiDP16-C113: A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of TMC435
The purpose of the study is to investigate the effect of moderate and severe hepatic impairment on the pharmacokinetics of TMC435.
- Trial name
- NCT01046058
- Testing
- TMC435
- Where
- 3 sites in United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Hepatitis C, Chronic
A Study of Combination Treatment With Peginterferon Alfa-2a (Pegasys) Plus Ribavirin (Copegus) in Participants With Chronic Hepatitis C
This 3-arm study assessed the safety and efficacy of combination treatment with peginterferon alfa-2a + ribavirin in participants with chronic hepatitis C.
- Trial name
- NCT00800748
- Testing
- Peginterferon alfa-2a, Ribavirin
- Where
- 35 sites in Czechia, Slovakia
- Volunteers
- 372 people
- Sponsor
- Hoffmann-La Roche
HIV Infections, Hepatitis C
The Safety and Effectiveness of a Two-Drug Combination in the Treatment of Patients With Hepatitis C Plus Advanced HIV Infections
To investigate the toxicity of interferon alfa-2b ( IFN alfa-2b ) in combination with nucleoside analog therapy in HIV-positive patients with chronic hepatitis C.
- Trial name
- NCT00001035
- Testing
- Interferon alfa-2b, Zidovudine, Zalcitabine
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Porphyria Cutanea Tarda, Hepatitis C
Harvoni Treatment Porphyria Cutanea Tarda
In the medical literature there case reports that Harvoni improves symptoms in patients with PCT. However, this has never been systematically tested.
- Trial name
- NCT03118674
- Testing
- Harvoni
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Wake Forest University Health Sciences
Chronic Hepatitis c
Anti-E1E2 (D32.10 Epitope-binding) Antibodies Status Prior Therapy Favors Direct-acting Antiviral Treatment Efficacy
The hypothesis was to check whether baseline anti-E1E2 antibodies could predict virological outcome in Hepatitis C virus (HCV)-infected patients receiving direct-acting antiviral treatment
- Trial name
- NCT03348059
- Testing
- Direct-acting antiviral therapy
- Where
- France
- Volunteers
- 103 people
- Sponsor
- Hospices Civils de Lyon
Alcohol Dependence, Chronic Hepatitis C
Study of the Effects of Motivational Enhancement Therapy on Alcohol Use in Chronic Hepatitis C Patients
The purpose of this study is to determine whether motivational enhancement therapy (MET) reduces alcohol use in a population of HCV-infected veterans who are currently drinking alcohol and have alcohol disorders.
- Trial name
- NCT00596960
- Testing
- Motivational Enhancement Therapy (MET), Health education
- Where
- 2 sites in United States
- Volunteers
- 139 people
- Sponsor
- US Department of Veterans Affairs
Chronic Genotype 4 HCV, Chronic Genotype 5 HCV
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 4 or 5 HCV Infection
This study is to evaluate the efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) in participants with chronic genotype 4 or 5 hepatitis C virus (HCV) infection as measured by the…
- Trial name
- NCT02081079
- Testing
- LDV/SOF
- Where
- 5 sites in France
- Volunteers
- 85 people
- Sponsor
- Gilead Sciences
Hepatitis C, Human Immunodeficiency Virus
Treatment of Acute Hepatitis C Virus in HIV Co-Infection
This study is designed to test the hypothesis that treatment of hepatitis C virus (HCV) infection during the first 6 months after acquiring HCV among people who already have pre-existing HIV infection will result in improved…
- Conditions
- Hepatitis C, Human Immunodeficiency Virus, HIV Infections
- Trial name
- NCT00845676
- Testing
- Pegylated interferon alfa-2a + Ribavirin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of California, San Francisco
Hepatitis C, Chronic
A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a)
This open-label, multicenter, phase IV study will evaluate the relationship between the drop in hemoglobin levels and sustained virological response in patients with chronic hepatitis C genotype 1 treated with Copegus (ribavirin)…
- Trial name
- NCT01585324
- Testing
- peginterferon alfa-2a [Pegasys], ribavirin [Copegus]
- Where
- Czechia
- Volunteers
- 30 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C Infection in HIV-Infected Persons, HIV Infections
PEG-Interferon a-2b + Ribavirin for Treatment of Chronic HRN 005 Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon
Objectives: Primary To compare the sustained virologic response (SVR) of PEGIntron plus ribavirin among patients receiving 48 weeks versus 72 weeks of therapy (defined as undetectable HCV RNA level 24 weeks after discontinuing…
- Trial name
- NCT00215891
- Testing
- PEG-Interferon a-2b + Ribavirin
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Hepatitis Resource Network
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.